Bio-Path (BPTH) Q1 2026 earnings summary

Executive summary

• Focused on RNAi nanoparticle drug development for oncology and obesity, with four drug candidates in development targeting cancer and metabolic diseases.

• Lead candidate prexigebersen is in a Phase 2 trial for AML, with promising interim results; other candidates target Bcl-2, STAT3, and obesity-related pathways.

• Operations paused and most employees furloughed as of June 2025 due to capital constraints; seeking additional financing and strategic partnerships.

Financial highlights

• Net loss for Q1 2026 was $0.3 million, a significant decrease from $2.9 million in Q1 2025, driven by reduced R&D and G&A expenses.

• Cash balance at March 31, 2026 was $0.1 million, up slightly from year-end 2025, but insufficient for 12 months of operations.

• Stockholders’ deficit increased to $(8.5) million as of March 31, 2026.

• No revenue generated in Q1 2026.

Outlook and guidance

• Expects to continue incurring significant operating losses and require substantial additional capital for ongoing and future clinical trials.

• Future operations depend on successful fundraising, licensing, or partnership agreements.